Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Meet Parkinson's Disease (PD) diagnosis consistent with UK PD diagnostic criteria~* Meet Hoehn and Yahr PD stage~* Good response to levodopa~* Stable regimen of anti-parkinson medications~* Are able to complete a Parkinson's disease diary~* If of childbearing potential(male and female), use an acceptable method of birth control~* Able and willing to sign an IRB/IEC approved informed consent~* Able and willing to understand study requirements, follow study instructions, attend all visits and undergo all planned tests.~Exclusion Criteria:~* Secondary or atypical Parkinson's~* Neurosurgical intervention for Parkinson's disease~* Treatment with apomorphine~* Treatment with anti-psychotic drugs~* Other abnormal findings on physical or neuro exam or history that in the opinion of the investigator would make subject unsuitable for the study or prejudice safety and efficacy evaluation~* MMSE less than 26~* Subjects with untreated or uncontrolled current episode of major depression~* Receipt of any anti-psychotic drugs greater than 1 month in the past 5 years or any exposure in past year (except for quetiapine at doses \<100mg per day)~* Women pregnant or lactating~* History of hepatitis, cholangitis~* Untreated or uncontrolled hypothyroidism or hyperthyroidism~* Drops in blood pressure requiring medication to maintain blood pressure~* Any clinically significant out of range laboratory evaluations~* Known sensitivity to the study medication or its components~* Suicide ideation or type 4 or type 5 on the Columbia suicide severity rating scale~* Finding of malignant melanoma on full body skin exam~* Impulse disorder conditions

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tozadenant (SYN115) 60 mg BID (Type: EXPERIMENTAL): Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
- Tozadenant (SYN115) 120 mg BID (Type: EXPERIMENTAL): Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
- Tozadenant (SYN115) 180 mg BID (Type: EXPERIMENTAL): Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
- Tozadenant (SYN115) 240 mg BID (Type: EXPERIMENTAL): Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
- Sugar Pill (Type: PLACEBO_COMPARATOR): White-coated, modified-oval placebo tablets.

Based on this trial design, predict the completion outcome and termination type (if applicable).